Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulocimab + Cadonilimab in advanced solid tumors
NCT05142423Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Nov 2021
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pulocimab in solid tumor, sponsored by Akeso, Inc. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 2 years and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
pulocimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05142423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142423.